{"id":"W2792297805","doi":"10.1158/1538-7445.sabcs17-gs1-02","title":"Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Medicine; Docetaxel; Cyclophosphamide; Internal medicine; Paclitaxel; Trastuzumab; Breast cancer; Chemotherapy; Oncology; Cohort; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.001013386,0.0006705536,0.00227718,0.0002325806,0.0003476196,0.00007593937,0.0002823263,0.0002234197,0.000125661],"category_scores_gemma":[0.0002748707,0.0003549107,0.00005802181,0.0006906666,0.003934434,0.00008648932,0.0002119702,0.0006080088,3.454067e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000719287,"about_ca_system_score_gemma":0.003319313,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02428715,"about_ca_topic_score_gemma":0.06005204,"domain_scores_codex":[0.9959036,0.0005475368,0.0007166902,0.001189378,0.0006977827,0.0009450846],"domain_scores_gemma":[0.9959832,0.0009371308,0.0008677689,0.0004570009,0.001463604,0.0002912932],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9530799,0.0008734069,0.01364129,0.0002769271,0.002796282,0.0001351909,0.01725964,0.000103835,0.006325122,0.00000135755,0.0001010395,0.005406051],"study_design_scores_gemma":[0.7785782,0.0193149,0.04900448,0.004177928,0.000370713,0.0001137467,0.03087284,0.00009026083,0.1166854,0.00001529773,0.00002614313,0.000750185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948727,0.0002945894,0.0001731268,0.0004142145,0.00004164267,0.003330883,0.0007486073,0.0000195005,0.0001046579],"genre_scores_gemma":[0.9931186,0.002045077,0.00245959,0.0001491913,0.0002193263,0.001741433,0.00002257696,0.000111525,0.000132695],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1745017,"threshold_uncertainty_score":0.9998903,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02801587497886952,"score_gpt":0.3486141053068592,"score_spread":0.3205982303279897,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}